UB Paderborn / Katalog / Suche / in CDI

Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients

Atherosclerosis, 2009-11, Vol.207 (1), p.250-254

2009

Volltextzugriff (PDF)

Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?

International journal of cardiology, 2014-10, Vol.176 (3), p.980-987

2014

Volltextzugriff (PDF)

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

Journal of thrombosis and haemostasis, 2009-06, Vol.7 (6), p.919-927

2009

Volltextzugriff (PDF)

Corrigendum to “Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients” [Atherosclerosis 207 (2009) 250–4]

Atherosclerosis, 2014-11, Vol.237 (1), p.30-30

2014

Volltextzugriff (PDF)

CV2 Is It Worth Spending Any Money to Develop a Biomarker Test to Optimize Statin Treatment for Individuals With an Intermediate Cardiovascular Risk?

Value in health, 2012-11, Vol.15 (7), p.A281-A281

2012

Volltextzugriff (PDF)

Einthoven dissertation prizes 2014

Netherlands heart journal, 2015-06, Vol.23 (6), p.342-344

2015

Volltextzugriff (PDF)

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

Atherosclerosis, 2019-06, Vol.285, p.135-146

2019

Volltextzugriff (PDF)

Recommendations and associated levels of evidence for statin use in primary prevention of cardiovascular disease: a comparison at population level of the ESC, ACC/AHA, USPSTF, and CCS Guidelines

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Retardation of angiographic progression of coronary artery disease by nifedipine

The Lancet (British edition), 1990-05, Vol.335 (8698), p.1109-1113

1990

Volltextzugriff (PDF)

P6213Differences in recommendations and associated level of evidence for statins in primary prevention of CVD according to the ACC/AHA 2013, CCS 2016, ESC 2016, and USPSTF 2016 clinical practice guidelines

European heart journal, 2017-08, Vol.38 (suppl_1)

2017

Volltextzugriff (PDF)

3098Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam Study

European heart journal, 2017-08, Vol.38 (suppl_1)

2017

Volltextzugriff (PDF)

Smoking cessation in European patients with coronary heart disease. Results from the EUROASPIRE IV survey: A registry from the European Society of Cardiology

International journal of cardiology, 2018-05, Vol.258, p.1-6

2018

Volltextzugriff (PDF)

n-3 Fatty Acids, Ventricular Arrhythmia–Related Events, and Fatal Myocardial Infarction in Postmyocardial Infarction Patients With Diabetes

Diabetes care, 2011-12, Vol.34 (12), p.2515-2520

2011

Volltextzugriff (PDF)

The prognosis of heart failure in the general population. The Rotterdam Study

European heart journal, 2001-08, Vol.22 (15), p.1318-1327

2001

Volltextzugriff (PDF)

Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study

European heart journal, 1999-03, Vol.20 (6), p.447-455

1999

Volltextzugriff (PDF)

Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study

International journal of impotence research, 2008-01, Vol.20 (1), p.92-99

2008

Volltextzugriff (PDF)

Switching a Catalyst System from Ethene Polymerization to Ethene Trimerization with a Hemilabile Ancillary Ligand

Angewandte Chemie (International ed.), 2001-07, Vol.40 (13), p.2516-2519

2001

Volltextzugriff (PDF)

Catalytic Trimerization of Ethene with Highly Active Cyclopentadienyl−Arene Titanium Catalysts

Organometallics, 2002-11, Vol.21 (23), p.5122-5135

2002

Volltextzugriff (PDF)

Measures of body composition and risk of heart failure in the elderly: The Rotterdam study

The Journal of nutrition, health & aging, 2011-05, Vol.15 (5), p.393-397

2011

Volltextzugriff (PDF)

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT

European heart journal, 2000-03, Vol.21 (5), p.371-381

2000

Volltextzugriff (PDF)

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker

European heart journal, 2002-02, Vol.23 (3), p.239-246

2002

Volltextzugriff (PDF)

Medium- and long-term outcome after coronary balloon angioplasty

Progress in cardiovascular diseases, 1994-03, Vol.36 (5), p.385-396

1994

Volltextzugriff (PDF)

Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey

European heart journal, 1999-11, Vol.20 (22), p.1630-1637

1999

Volltextzugriff (PDF)

C−H Bond Activation Processes in Cationic and Neutral Titanium Benzyl Compounds with Cyclopentadienyl−Arene Ligands

Organometallics, 2002-12, Vol.21 (25), p.5564-5575

2002

Volltextzugriff (PDF)

Diagnostic interpretation of electrocardiograms in population-based research: Computer program research physicians, or cardiologists?

Journal of clinical epidemiology, 1997-08, Vol.50 (8), p.947-952

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients

Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

Corrigendum to “Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients” [Atherosclerosis 207 (2009) 250–4]

CV2 Is It Worth Spending Any Money to Develop a Biomarker Test to Optimize Statin Treatment for Individuals With an Intermediate Cardiovascular Risk?

Einthoven dissertation prizes 2014

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

Recommendations and associated levels of evidence for statin use in primary prevention of cardiovascular disease: a comparison at population level of the ESC, ACC/AHA, USPSTF, and CCS Guidelines

Retardation of angiographic progression of coronary artery disease by nifedipine

P6213Differences in recommendations and associated level of evidence for statins in primary prevention of CVD according to the ACC/AHA 2013, CCS 2016, ESC 2016, and USPSTF 2016 clinical practice guidelines

3098Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam Study

Smoking cessation in European patients with coronary heart disease. Results from the EUROASPIRE IV survey: A registry from the European Society of Cardiology

n-3 Fatty Acids, Ventricular Arrhythmia–Related Events, and Fatal Myocardial Infarction in Postmyocardial Infarction Patients With Diabetes

The prognosis of heart failure in the general population. The Rotterdam Study

Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study

Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study

Switching a Catalyst System from Ethene Polymerization to Ethene Trimerization with a Hemilabile Ancillary Ligand

Catalytic Trimerization of Ethene with Highly Active Cyclopentadienyl−Arene Titanium Catalysts

Measures of body composition and risk of heart failure in the elderly: The Rotterdam study

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker

Medium- and long-term outcome after coronary balloon angioplasty

Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey

C−H Bond Activation Processes in Cationic and Neutral Titanium Benzyl Compounds with Cyclopentadienyl−Arene Ligands

Diagnostic interpretation of electrocardiograms in population-based research: Computer program research physicians, or cardiologists?

Suchergebnisse filtern